Soleno Therapeutics INC Schedule 13G passive stakes

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 2.0% of Soleno Therapeutics Inc.'s common stock as of March 31, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 4.45% of Soleno Therapeutics Inc. common stock as of March 31, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 8.6% of Soleno Therapeutics, Inc. common stock as of March 31, 2026.

State Street Corporation has reported beneficial ownership of 5.2% of Soleno Therapeutics Inc.'s common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 1,205,303 common shares, representing 2.3% of the class, in Soleno Therapeutics, Inc. as of April 30, 2026.

FMR LLC, through its subsidiaries, has disclosed a beneficial ownership of 0.4% of Soleno Therapeutics Inc.'s common stock as of April 30, 2026.

FMR LLC and Abigail P. Johnson have reported a significant beneficial ownership stake of 11.2% in Soleno Therapeutics Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Soleno Therapeutics Inc. following an internal realignment.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 5.4% beneficial ownership stake in Soleno Therapeutics Inc., holding 2.9 million shares for investment purposes.

Wellington Management Group LLP and its affiliates have reported a 6.2% beneficial ownership stake in Soleno Therapeutics, Inc. common stock.

Vivo Opportunity Fund Holdings, L.P. and its affiliates reported a 4.2% beneficial ownership stake in Soleno Therapeutics, Inc. common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting an increased beneficial ownership of 11.4% in Soleno Therapeutics, Inc. as of September 30, 2025.

Adage Capital Management, L.P. and its principals have reduced their beneficial ownership in Soleno Therapeutics Inc. to 2.64% of common stock.

The Vanguard Group has reported a 5.28% beneficial ownership stake in Soleno Therapeutics Inc., holding 2,807,149 shares of common stock.

Nantahala Capital Management and its managing members disclosed a 1.99% passive ownership stake in Soleno Therapeutics Inc. as of June 30, 2025.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership stake in Soleno Therapeutics Inc.

Janus Henderson Group plc has increased its beneficial ownership in Soleno Therapeutics, Inc. to 10.5% of common stock.

Avoro Capital Advisors and Behzad Aghazadeh have reduced their beneficial ownership in Soleno Therapeutics to 4.1%, as disclosed in an amended Schedule 13G filing.

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have updated their beneficial ownership in Soleno Therapeutics, Inc. to 7.4%.

Adage Capital Management, L.P. and its principals have reported a 7.10% beneficial ownership stake in Soleno Therapeutics Inc., holding 3,575,964 shares.

FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Soleno Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have reported a passive 6.6% beneficial ownership stake in Soleno Therapeutics Inc. common stock.

BlackRock, Inc. has filed a Schedule 13G, revealing a 5.5% beneficial ownership stake in Soleno Therapeutics Inc.'s common stock.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a beneficial ownership of 11.2% of Soleno Therapeutics, Inc.'s common stock as of March 31, 2025.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting a 5.2% beneficial ownership stake in Soleno Therapeutics Inc. as of March 31, 2025.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has reported a passive beneficial ownership of 9.58% in Soleno Therapeutics Inc., totaling 4,392,696 shares of common stock.

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a 5.6% beneficial ownership stake in Soleno Therapeutics, Inc. as of March 31, 2025.

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have filed an amended Schedule 13G disclosing a 9.7% beneficial ownership stake in Soleno Therapeutics, Inc.

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in Soleno Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a 12.0% beneficial ownership stake in Soleno Therapeutics, Inc. as of December 31, 2024.